ライフサイエンスコーパス: mitogen-activated protein

1 Chemical inhibition of IkappaB kinase (IKK), mitogen-activated protein extracellular signal-regulated

2 regulatory effects of BCL6 on both MEK-ERK (mitogen-activated protein/extracellular signal-regulated

3 screen identified multiple components of the mitogen activated protein kinase (MAPK) pathway enhancin

4 extracellular signal regulated kinase (ERK)/mitogen activated protein kinase (MAPK) pathway.

5 nical nuclear factor kappa B (NF-kappaB) and mitogen activated protein kinase (MAPK) pathways have be

6 ncers contain genetic alterations within the Mitogen Activated Protein Kinase (MAPK) signaling networ

7 Mitogen activated protein kinase 4 (MPK4) is a multifunc

8 Messenger RNA expression levels of p38 mitogen activated protein kinase and nuclear factor kapp

9 uclear cells of sepsis patients, whereas p38 mitogen activated protein kinase messenger RNA was up-re

10 In neutrophils of sepsis patients, mitogen activated protein kinase phosphatase-1 messenger

11 sis factor-alpha-induced protein 3 (A20) and mitogen activated protein kinase phosphatase-1 were dete

12 rhabditis elegans, we implicate the atypical mitogen activated protein kinase, SWIP-13, in DAT regula

13 ion of extracellular signal-regulated kinase/mitogen-activated protein kinase (ERK MAPK).

14 ia extracellular signal-regulated kinase 1/2 mitogen-activated protein kinase (ERK1/2 MAPK)-dependent

15 In this study, we identify a complete mitogen-activated protein kinase (MAPK or MPK) cascade,

16 mune signaling, including phosphorylation of mitogen-activated protein kinase (MAPK) 3 (MPK3) and MPK

17 MADD, the mitogen-activated protein kinase (MAPK) activating death

18 ls converging at the MOR promoter, involving mitogen-activated protein kinase (MAPK) activation and m

19 D family members 2, 3, and 4 (SMAD2/3/4) and mitogen-activated protein kinase (MAPK) activities, whic

20 was caused by an elevation in macrophage p38 mitogen-activated protein kinase (MAPK) activity.

21 through elevated and sustained activation of mitogen-activated protein kinase (MAPK) and AKT.

22 The expression of mitogen-activated protein kinase (MAPK) and endothelial

23 species (ROS) production, and activated p38 mitogen-activated protein kinase (MAPK) and p53.

24 Mutations at both interfaces interfered with mitogen-activated protein kinase (MAPK) and phosphoinosi

25 d proliferative (PRO) phenotypes linked with mitogen-activated protein kinase (MAPK) and signal trans

26 used it to analyze a set of D-motif peptide-mitogen-activated protein kinase (MAPK) associations to

27 Activation of the mitogen-activated protein kinase (MAPK) c-Jun N-terminal

28 e to mating pheromone activates a prototypic mitogen-activated protein kinase (MAPK) cascade and trig

29 idopsis, an extremely functionally redundant mitogen-activated protein kinase (MAPK) cascade is requi

30 reatment identified robust activation of p38 mitogen-activated protein kinase (MAPK) downstream of PK

31 daptors to regulate AT1R internalization and mitogen-activated protein kinase (MAPK) ERK1/2 activatio

32 increased levels of total and phosphorylated mitogen-activated protein kinase (MAPK) family members s

33 e a conserved feature of some members of the mitogen-activated protein kinase (MAPK) family.

34 Previous studies showed that activation of mitogen-activated protein kinase (MAPK) in diabetes prom

35 KO mice with enhanced phosphorylation of p38 mitogen-activated protein kinase (MAPK) in podocytes.

36 Smk1 is a meiosis-specific mitogen-activated protein kinase (MAPK) in Saccharomyces

37 Smk1 is a meiosis-specific mitogen-activated protein kinase (MAPK) in yeast that co

38 The anti-inflammatory potential of p38 mitogen-activated protein kinase (MAPK) inhibitors was c

39 ype I priming, or the combination of Src and mitogen-activated protein kinase (MAPK) inhibitors, whic

40 Mitogen-activated protein kinase (MAPK) interacting kina

41 artially rescued by constitutively activated mitogen-activated protein kinase (MAPK) kinase kinase YO

42 Microbial pathogens often target the host mitogen-activated protein kinase (MAPK) network to suppr

43 paired the activity of key components of the mitogen-activated protein kinase (MAPK) pathway (p38 and

44 WASP-deficient lymphoma showed increased mitogen-activated protein kinase (MAPK) pathway activati

45 ling pathway, beta-arrestin recruitment, and mitogen-activated protein kinase (MAPK) pathway activati

46 brane (PM) correlates with activation of the mitogen-activated protein kinase (MAPK) pathway and subs

47 Mitogen-activated protein kinase (MAPK) pathway antagoni

48 hodiesterase inhibitor and also modifies the mitogen-activated protein kinase (MAPK) pathway by downr

49 ptor protein tyrosine phosphatase within the mitogen-activated protein kinase (MAPK) pathway controll

50 arget the receptor tyrosine kinase (RTK)/Ras/mitogen-activated protein kinase (MAPK) pathway have led

51 "paradoxical" upregulation of the downstream mitogen-activated protein kinase (MAPK) pathway in cance

52 TGF-beta depends on RAS and mitogen-activated protein kinase (MAPK) pathway inputs f

53 The mitogen-activated protein kinase (MAPK) pathway is a key

54 Identifying additional mitogen-activated protein kinase (MAPK) pathway regulato

55 nsition (EMT), mediated, in part, by the p38 mitogen-activated protein kinase (MAPK) pathway respondi

56 Signaling analysis indicated decreased mitogen-activated protein kinase (MAPK) pathway signalin

57 ic cells (DCs) with constitutively activated mitogen-activated protein kinase (MAPK) pathway signalin

58 that are marked by diverse mutations in the mitogen-activated protein kinase (MAPK) pathway(1,2).

59 BRAF, a kinase in the mitogen-activated protein kinase (MAPK) pathway, is muta

60 umor growth by constitutively activating the mitogen-activated protein kinase (MAPK) pathway.

61 ic alterations that converge to activate the mitogen-activated protein kinase (MAPK) pathway.

62 or (BDNF)-activated enzyme downstream of the mitogen-activated protein kinase (MAPK) pathway.

63 tivated kinase Ste20p, Cdc42p also regulates mitogen-activated protein kinase (MAPK) pathways (mating

64 Mitogen-activated protein kinase (MAPK) pathways are con

65 Cellular signaling pathways, including the mitogen-activated protein kinase (MAPK) pathways, are re

66 dependent on the activation of the NF-kB and mitogen-activated protein kinase (MAPK) pathways, which

67 pattern recognition receptors activates the mitogen-activated protein kinase (MAPK) pathways, which

68 athways, whereas FGFR2b relied on downstream mitogen-activated protein kinase (MAPK) pathways.

69 nhancer of activated B cells (NF-kappaB) and mitogen-activated protein kinase (MAPK) pathways.

70 The mitogen-activated protein kinase (MAPK) phosphatases (MK

71 These express a mitogen-activated protein kinase (MAPK) programme that w

72 ll fusion, is mediated by Gbetagamma and the mitogen-activated protein kinase (MAPK) scaffold protein

73 Mitogen-activated protein kinase (MAPK) scaffold protein

74 In the absence of RASA1, dysregulated Ras mitogen-activated protein kinase (MAPK) signal transduct

75 PF included extracellular matrix remodeling, Mitogen-activated protein kinase (MAPK) signaling and AL

76 strains, we show that candidalysin activates mitogen-activated protein kinase (MAPK) signaling and ch

77 AS, and BRAF mutations which activate p44/42 mitogen-activated protein kinase (MAPK) signaling are fo

78 orted that kinase-dead BRAF variants amplify mitogen-activated protein kinase (MAPK) signaling by dim

79 to interact with both survival and apoptotic mitogen-activated protein kinase (MAPK) signaling cascad

80 ated calcium channel Cacophony (Cac) and the mitogen-activated protein kinase (MAPK) signaling cascad

81 ed by PTPN11, plays an essential role in RAS-mitogen-activated protein kinase (MAPK) signaling during

82 PD-L1 blockade with inhibition of oncogenic mitogen-activated protein kinase (MAPK) signaling may re

83 sor that is differentially regulated through mitogen-activated protein kinase (MAPK) signaling or gen

84 4b to act as a negative regulator of the RAS/mitogen-activated protein kinase (MAPK) signaling pathwa

85 S. cerevisiae plays crucial roles in various mitogen-activated protein kinase (MAPK) signaling pathwa

86 At the molecular level, besides the mitogen-activated protein kinase (MAPK) signaling pathwa

87 tein, VopA, has potent inhibitory effects on mitogen-activated protein kinase (MAPK) signaling pathwa

88 ally, inhibition of the PI3K, but not of the mitogen-activated protein kinase (MAPK) signaling pathwa

89 AF gene fusions that aberrantly activate the mitogen-activated protein kinase (MAPK) signaling pathwa

90 and activator of transcription 3 (STAT3) and mitogen-activated protein kinase (MAPK) signaling pathwa

91 kinase, p38, and c-Jun amino-terminal kinase mitogen-activated protein kinase (MAPK) signaling to eli

92 Elevated Pi activates mitogen-activated protein kinase (MAPK) signaling, encom

93 of RAF proto-oncogene, Ser/Thr kinase (Raf)-mitogen-activated protein kinase (MAPK) signaling, induc

94 c) Homology Phosphatase 2 (Shp2) to activate Mitogen-Activated Protein Kinase (MAPK) signaling, which

95 of Bmf expression, predominantly via p44/42 mitogen-activated protein kinase (MAPK) signaling.

96 cules, thus suppressing Raf-1 activation and mitogen-activated protein kinase (MAPK) signaling.

97 with genes implicated in focal adhesion and mitogen-activated protein kinase (MAPK) signaling.

98 1 (CK1) sites Cx43(S325A/328Y/330A), and the mitogen-activated protein kinase (MAPK) sites Cx43(S255/

99 gh autophosphorylation and activation of p38 mitogen-activated protein kinase (MAPK) via a non-canoni

100 identified NF-kappaB activator 1 (Act1), p38 mitogen-activated protein kinase (MAPK), Jun NH2-termina

101 ake of bacteria, which required PDK1, and of mitogen-activated protein kinase (MAPK)- and nuclear fac

102 its rapid basal turnover in neurons and that mitogen-activated protein kinase (MAPK)-dependent phosph

103 kinase (IKK), c-jun N-terminal kinase (JNK), mitogen-activated protein kinase (MAPK)-extracellular re

104 l GTPases, p21-activated kinase, and the p38 mitogen-activated protein kinase (MAPK)-MAPK-activated p

105 of all pathogenic non-Dsg AuAbs involved p38 mitogen-activated protein kinase (MAPK)-mediated phospho

106 which transcription factors are released by mitogen-activated protein kinase (MAPK)-stimulated acety

107 lung injury is blunted by inhibitors of p38 mitogen-activated protein kinase (MAPK).

108 fungi that regulates the downstream HOG/p38 mitogen-activated protein kinase (MAPK).

109 Inhibition of MEK (mitogen-activated protein kinase (MAPK)/ERK kinase) afte

110 Cystic kidneys showed increased mitogen-activated protein kinase (MAPK)/extracellular si

111 (PI3K)/Akt serine/threonine kinase (Akt) and mitogen-activated protein kinase (MAPK)/extracellular si

112 On the basis of our previous work on mitogen-activated protein kinase (MAPK)/extracellular si

113 an extremely potent allosteric inhibitor of mitogen-activated protein kinase (MAPK)/extracellular-si

114 f the JCI, Yokota et al. reveal that the p38 mitogen-activated protein kinase (MAPK)/IRE1alpha/XBP1 a

115 n of oncogenic Ras(V12) activates downstream mitogen-activated protein kinase (MEK-ERK) signaling to

116 Mitogen-activated protein kinase (MPK) cascades are cons

117 Increases in the phosphorylation of p38 mitogen-activated protein kinase (p38 MAPK) and decrease

118 NASH development and the involvement of p38 mitogen-activated protein kinase (p38) activated by neut

119 CyTP genes is mediated by the conserved p38 mitogen-activated protein kinase (p38-MAPK) pathway.

120 Signal transduction pathways mediated by p38 mitogen-activated protein kinase (p38MAPK), extracellula

121 tly driven by genetic alterations in the RAS-mitogen-activated protein kinase (RAS/MAPK) pathway yet

122 hed in synaptic function and converge on Ras/mitogen-activated protein kinase (Ras/MAPK) signaling.

123 ovo missense variants in MAPK1, encoding the mitogen-activated protein kinase 1 (i.e., extracellular

124 l myenteric plexi and phosphorylation (p) of mitogen-activated protein kinase 1 (MAPK1) in the enteri

125 e P (SP), S100beta, GFAP, and phosphorylated mitogen-activated protein kinase 1 (pERK) were assessed

126 proteins, auxin stabilizes IAA33 protein via MITOGEN-ACTIVATED PROTEIN KINASE 14 (MPK14) and does not

127 Here, we report that mitogen-activated protein kinase 3 (MPK3) and MPK6 inter

128 e use Nicotiana attenuata plants silenced in mitogen-activated protein kinase 4 (irMPK4) - with low w

129 The strongest regulator of invasion was mitogen-activated protein kinase 4 (MAP4K4).

130 Previously, we demonstrated that Arabidopsis mitogen-activated protein kinase 6 (MPK6) and MPK3 play

131 elated prognostic proteins, particularly the mitogen-activated protein kinase 6, probable protein pho

132 samples and xenograft mouse models revealed mitogen-activated protein kinase 7/matrix metallopeptida

133 beta-arrestin-dependent signaling responses, mitogen-activated protein kinase [i.e., extracellular si

134 g22, PLC2-silenced plants maintain wild-type mitogen-activated protein kinase activation and PHI1, WR

135 nd extracellular signal-regulated kinase 1/2 mitogen-activated protein kinase activation at the human

136 Mitogen-activated protein kinase activation by IL-8 has

137 Moreover, p38 mitogen-activated protein kinase activation emerges as a

138 for Ptpn6 in the negative regulation of p38 mitogen-activated protein kinase activation to control t

139 es G protein-coupled calcium ion signals and mitogen-activated protein kinase activity, and that its

140 ntracellular signaling pathways, such as the mitogen-activated protein kinase and AKT signaling casca

141 We targeted the mitogen-activated protein kinase and phosphatidylinosito

142 h levels of reactive oxygen species in a p38 mitogen-activated protein kinase and phosphatidylinosito

143 e ability of pharmacologic inhibition of the mitogen-activated protein kinase and PI3'K pathways to i

144 via the gp130 signaling receptor, activating mitogen-activated protein kinase and signal transducer a

145 is revealed significant up-regulation of the mitogen-activated protein kinase and transforming growth

146 ulation in endothelial cells via JNK and p38 mitogen-activated protein kinase but not NF-kappaB.

147 identified OsPT8 as an interactor of a rice mitogen-activated protein kinase BWMK1, which is a regul

148 -X-C motif chemokine ligand 12 activates the mitogen-activated protein kinase extracellular-signal-re

149 n N-terminal kinase (JNK) is a member of the mitogen-activated protein kinase family and controls var

150 of CDKN2C and TP53, and mutations affecting mitogen-activated protein kinase genes.

151 preceded by decreased phosphorylation of p38 mitogen-activated protein kinase in HMuSC treated with C

152 eased proliferation and dysregulation of p38 mitogen-activated protein kinase in satellite cells comm

153 egulated protein kinase 1/2 (ERK1/2) and p38 mitogen-activated protein kinase in T lymphocytes.

154 ed by the accumulation of phosphorylated p38 mitogen-activated protein kinase in the nucleus, which d

155 Conversely, after dual MET/mitogen-activated protein kinase inhibition, tumor growt

156 vides a rationale for combining pan-ERBB and mitogen-activated protein kinase inhibitors as a therape

157 c target of rapamycin complex 1 (mTORC1) and mitogen-activated protein kinase interacting kinase (MNK

158 Finally, it reveals that mitogen-activated protein kinase interacting kinase-1 ha

159 tion of lipid A limits the activation of the mitogen-activated protein kinase Jun N-terminal protein

160 tor of transcription (STAT) (ruxolitinib) or mitogen-activated protein kinase kinase (MEK) (trametini

161 ines had IC(50) values less than 7 nM to the mitogen-activated protein kinase kinase (MEK) 1/2 inhibi

162 mutational status, and response to B-Raf and mitogen-activated protein kinase kinase (MEK) inhibition

163 We show that the mitogen-activated protein kinase kinase (MEK) inhibitor

164 As validation, distinct mitogen-activated protein kinase kinase (MEK) inhibitors

165 therapy with B-Raf proto-oncogene (BRAF) and mitogen-activated protein kinase kinase (MEK) inhibitors

166 e/threonine-specific protein kinases (pRAF), mitogen-activated protein kinase kinase (pMEK), protein

167 A recently developed photoswitchable mitogen-activated protein kinase kinase 1 (MEK1) enzyme

168 Both VE-cadherin-silenced and mitogen-activated protein kinase kinase 1 (MEK1)-silence

169 ffector PI3K but instead require active MEK (mitogen-activated protein kinase kinase 1) signaling.

170 Hyperactivation of mitogen-activated protein kinase kinase 1/2 (MEK1/2), bu

171 ivated protein kinase kinase kinase 3)-MEK5 (mitogen-activated protein kinase kinase 5)-ERK5 (extrace

172 found REX1 to bind to the promoter region of mitogen-activated protein kinase kinase 6 (MKK6), thereb

173 ently described their potential in targeting mitogen-activated protein kinase kinase 7 (MKK7).

174 gamma) intraperitoneally for 3 d or with the mitogen-activated protein kinase kinase inhibitor selume

175 2 depletion in ECs elicited increased MEKK3 (mitogen-activated protein kinase kinase kinase 3)-MEK5 (

176 restingly, we observed that knockdown of the mitogen-activated protein kinase kinase kinase 4 (MAP3K4

177 Among the differentially expressed kinases, mitogen-activated protein kinase kinase kinase kinase 4

178 Mitogen-activated protein kinase kinase kinase kinase-4

179 Mitogen-Activated Protein Kinase Kinase Kinase Kinase-4

180 r their mechanisms of action using selective mitogen-activated protein kinase kinase MEK1/2, MEK5, an

181 s pyruvate dehydrogenase kinase 1, Akt, Raf, mitogen-activated protein kinase kinase, and ERK1/2.

182 particular, we report synergistic effects of mitogen-activated protein kinase kinase, ribosomal S6 ki

183 tical residues within the catalytic loops of mitogen-activated protein kinase kinases (MAPKKs).

184 Although LF is known to cleave mitogen-activated protein kinase kinases (MEKs/MKKs) and

185 -in-class von Hippel-Lindau (VHL)-recruiting mitogen-activated protein kinase kinases 1 and 2 (MEK1/2

186 uce new KRAS(G12C) in response to suppressed mitogen-activated protein kinase output.

187 Furthermore, phosphorylation of the mitogen-activated protein kinase p38 was enhanced and ph

188 icity phosphatase 1, impairs the activity of mitogen-activated protein kinase p38, increases the acti

189 rticularly, we found that alterations of the mitogen-activated protein kinase pathway (KRAS and NRAS

190 Finally, we demonstrate mitogen-activated protein kinase pathway activation and

191 ward beta-arrestin recruitment and increased mitogen-activated protein kinase pathway activation.

192 llular signal-regulated protein kinase (ERK) mitogen-activated protein kinase pathway and that ERK in

193 ted, at least in part, via activation of the mitogen-activated protein kinase pathway following calci

194 M) in 60%, and phosphatidylinositol 3-kinase/mitogen-activated protein kinase pathway genes (eg, ERBB

195 breast cancer, and inhibitors of the RAS/RAF/mitogen-activated protein kinase pathway in RAS-mutant c

196 phosphorylation of focal adhesion kinase and mitogen-activated protein kinase pathway leading to enha

197 th the extracellular signal-regulated kinase mitogen-activated protein kinase pathway that provides a

198 ectively, these findings demonstrate the ERK mitogen-activated protein kinase pathway to be integrall

199 ibed the paradoxical triggering of the human mitogen-activated protein kinase pathway when a small-mo

200 extracellular signal-regulated kinase (ERK) mitogen-activated protein kinase pathway, consistent wit

201 ransducer and activator of transcription and mitogen-activated protein kinase pathways to regulate ce

202 y, pyrin domain-containing-3, and downstream mitogen-activated protein kinase pathways.

203 enotype was characterized by upregulation of mitogen-activated protein kinase pathways.

204 ofin (ARN), an antirheumatic drug, to induce mitogen-activated protein kinase phosphatase (MKP)-1 exp

205 bacterium tuberculosis (Mtb) by facilitating mitogen-activated protein kinase phosphatase 1 (MKP-1)-d

206 ed with a pharmacological agent that induces mitogen-activated protein kinase phosphatase have potent

207 past several years has elucidated a role for mitogen-activated protein kinase phosphatase to regulate

208 The Erk mitogen-activated protein kinase plays diverse roles in

209 2, PtrHAB13 and PtrHAB14 interacted with the mitogen-activated protein kinase protein PtrMPK7.

210 otein kinase C, cyclin-dependent kinase, and mitogen-activated protein kinase showed increased phosph

211 nger NHFs, PDAC cells exhibited increases in mitogen-activated protein kinase signaling and cellular

212 E-cadherin/epidermal growth factor receptor/mitogen-activated protein kinase signaling axis.

213 folded protein response, glycolysis, and the mitogen-activated protein kinase signaling cascade.

214 d causal link between LZTR1 dysfunction, RAS-mitogen-activated protein kinase signaling hyperactivity

215 e renin-angiotensin system in the kidney and mitogen-activated protein kinase signaling in the heart.

216 terations in genes whose products are in the mitogen-activated protein kinase signaling pathway and a

217 g mechanism is a gain-of-function of the RAS-mitogen-activated protein kinase signaling pathway.

218 roteins in receptor tyrosine kinase, RAS, or mitogen-activated protein kinase signaling pathways.

219 se 4 (MAP3K4) gene, which contributes to p38 mitogen-activated protein kinase signaling, sensitized c

220 ed with wild-type mice, along with decreased mitogen-activated protein kinase signaling, tumor angiog

221 suppression of the inflammatory response and mitogen-activated protein kinase signaling.

222 extracellular signal-regulated kinase (ERK)-mitogen-activated protein kinase signaling.

223 cytoskeletal structures, and hyperactivated mitogen-activated protein kinase signaling.

224 ignalling, cell cycle regulatory signalling, mitogen-activated protein kinase signalling and pathways

225 nsducer and activator of transcription 3 and mitogen-activated protein kinase signalling in an inocul

226 diverse modes of injury converge on p38alpha mitogen-activated protein kinase within the fibroblast t

227 apoptosis signal-regulating kinase 1 and p38 mitogen-activated protein kinase) activation.

228 of BRD4 is controlled, in part, by p38 MAPK (mitogen-activated protein kinase) and provide evidence o

229 K (RAS-extracellular signal-regulated kinase/mitogen-activated protein kinase) pathway integrates gro

230 ion of 101 gene transcripts, including MAPK (mitogen-activated protein kinase) signaling targets, HOP

231 efective in activating PAK3 as well as MAPK (mitogen-activated protein kinase).

232 s extracellular signal-regulated kinase 1/2, mitogen-activated protein kinase, and Src, shown by immu

233 Mitogen-activated protein kinase, kinase, kinase- 19 (MA

234 In contrast, mitogen-activated protein kinase, Src tyrosine kinase, a

235 eltaPMN) neutrophils displayed increased p38 mitogen-activated protein kinase-dependent Ripk1-indepen

236 al-related kinase 1/2 (pERK1/2), a marker of mitogen-activated protein kinase-ERK signal transduction

237 Targeting of the mitogen-activated protein kinase-interacting kinase (MNK

238 cellular senescence and is activated by p38 mitogen-activated protein kinase.

239 it also inhibited the phosphorylation of p38 mitogen-activated protein kinase.

240 receptor also known as TrkA that upregulates mitogen-activated protein kinase.

241 otein expression that was attenuated by MEK (mitogen-activated protein kinase/extracellular signal-re

242 al growth factor receptor (EGFR), as EGFR or mitogen-activated protein kinase/extracellular signal-re

243 Subsequently, activation of a mitogen-activated protein kinase/extracellular signal-re

244 with the BRAF inhibitor vemurafenib and the mitogen-activated protein kinase/extracellular signal-re

245 ed that the rapidly accelerated fibrosarcoma/mitogen-activated protein kinase/extracellular signal-re

246 al stem-like (MSL) lineage downregulates the mitogen-activated protein kinase/extracellular signal-re

247 Further studies revealed that mitogen Activated Protein Kinase9 (CaMPK9) phosphorylate

248 biquitously expressed member of the atypical mitogen activated protein kinases (MAPKs) and the physio

249 -inflammatory pathways such as NF-kappaB and mitogen activated protein kinases (MAPKs), and the subse

250 MAP3K4 functions upstream of the p38 and JNK mitogen activated protein kinases (MAPKs).

251 ciated protein kinase 70 (ZAP-70), and three mitogen-activated protein kinases (extracellular signal-

252 cular chondrocytes via the inhibition of p38 mitogen-activated protein kinases (MAPK) and increasing

253 transcription factors are phosphorylated by mitogen-activated protein kinases (MAPK) in their transa

254 mapping revealed the involvement of K-RAS in mitogen-activated protein kinases (MAPK) pathway.

255 Mitogen-activated protein kinases (MAPK) such as p38 and

256 ar signal-regulated kinase 1 and 2 (ERK1/2), mitogen-activated protein kinases (MAPK), leading to unc

257 relatively rare member of the JNK family of mitogen-activated protein kinases (MAPK), phosphorylates

258 d kinase (ERK)/C-Jun N-terminal kinase (JNK) mitogen-activated protein kinases (MAPK)] were assessed

259 ral detail on docking interactions involving mitogen-activated protein kinases (MAPKs) and their subs

260 KIM-PTPs bind and dephosphorylate mitogen-activated protein kinases (MAPKs) and thereby cr

261 The molecular actions of mitogen-activated protein kinases (MAPKs) are ultimately

262 s diverse kinase pathways, which include the mitogen-activated protein kinases (MAPKs) ERK and p38, t

263 Mitogen-activated protein kinases (MAPKs) form important

264 Cellular mitogen-activated protein kinases (MAPKs) have been show

265 The catalytic activity of mitogen-activated protein kinases (MAPKs) is dynamically

266 t/MKP-1 pathway results in the inhibition of mitogen-activated protein kinases (MAPKs) JNK and p38.

267 Mitogen-activated protein kinases (MAPKs) mediate numero

268 we show that the rapid activation of clade-A mitogen-activated protein kinases (MAPKs) MPK3 and MPK6

269 Mitogen-activated protein kinases (MAPKs) regulate essen

270 Of note, two mitogen-activated protein kinases (MAPKs), extracellular

271 Two flg22-responsive mitogen-activated protein kinases (MAPKs), MPK3 and MPK6

272 (DUSP1), an endogenous negative regulator of mitogen-activated protein kinases (MAPKs), resulting in

273 some are under transcriptional regulation by mitogen-activated protein kinases (MAPKs).

274 nd ROS signals compromised the activation of mitogen-activated protein kinases (MPKs) 1/2 in leaves.

275 sion of sequestosome 1 (p62) and phospho-p38 mitogen-activated protein kinases (p-p38) showed a signi

276 , oxidative stress, early phosphorylation of mitogen-activated protein kinases and Akt, and upregulat

277 were not affected in PAMP/DAMP activation of mitogen-activated protein kinases and expression of the

278 Activation of mitogen-activated protein kinases and NFkappaB signaling

279 p38 mitogen-activated protein kinases are key mediators of e

280 lular signal-regulated kinase), JNK, and p38 mitogen-activated protein kinases as well as NFkappaB (n

281 lear factor-kappaB, as well as activation of mitogen-activated protein kinases pathways.

282 st transdifferentiation by activation of p38 mitogen-activated protein kinases resulting in upregulat

283 ptation and stress tolerance, and in several mitogen-activated protein kinases signaling pathways inc

284 of reactive oxygen species and activation of mitogen-activated protein kinases upon exposure to flg22

285 ing a dual-specificity phosphatase targeting mitogen-activated protein kinases, as a type 2 diabetes

286 Mitogen-activated protein kinases, including c-Jun NH2-t

287 HAI1 or by HAI1-regulated kinases including mitogen-activated protein kinases, sucrose non-fermentin

288 ut increased cell invasion and activation of mitogen-activated protein kinases.

289 Disruption or knockdown of an Msb2-dependent mitogen-activated protein (MAP) kinase (HOG2) and an APS

290 ch engages the c-Jun N-terminal kinase (JNK) mitogen-activated protein (MAP) kinase and Fos and Jun t

291 t requires the c-Jun N-terminal kinase (JNK) mitogen-activated protein (MAP) kinase and the transcrip

292 magnetic resonance (NMR) measurements of the mitogen-activated protein (MAP) kinase ERK2 have shown t

293 Pharmacological inhibition of the mitogen-activated protein (MAP) kinase extracellular sig

294 e Using this approach, we identified the p38 mitogen-activated protein (MAP) kinase pathway and autop

295 duction of reactive oxygen species (ROS) and mitogen-activated protein (MAP) kinase phosphorylation,

296 ptosis, and its expression is facilitated by mitogen-activated protein (MAP) kinase-activated protein

297 ive responses characterized by activation of mitogen-activated protein (MAP) kinases and nuclear fact

298 ts in the UPR, such as activation of the JNK mitogen-activated protein (MAP) kinases or the pseudokin

299 KK1 can trigger various responses, including mitogen-activated protein (MAP) kinases, NF-kappaB signa

300 ns and a homozygous nonsense mutation in the mitogen-activated protein triple kinase ZAK.